Geron Announces Phase 1 Findings From Two-Part IMproveMF Study Suggesting Tolerability Of RYTELO In Combination With Ruxolitinib As Frontline Therapy In Patients With Myelofibrosis Presented At ASH; In The Dose Escalation Part 1 Of The Study, No Dose-Limiting Toxicities Were Observed And The PK Profiles Were Similar To Those Reported For Previous Monotherapy Studies Of Imetelstat And Ruxolitinib
- In the dose escalation Part 1 of the study, no dose-limiting toxicities were observed and the PK profiles were similar to those reported for previous monotherapy studies of imetelstat and ruxolitinib
- Based on the safety profile, imetelstat 9.4 mg/kg dosed every four weeks with ruxolitinib was the selected dose for the dose expansion Part 2 of the study, which is currently enrolling patients
- Geron is also evaluating the potential of imetelstat in the separate Phase 3 IMpactMF trial of patients with JAKi relapsed/refractory MF, which is >70% enrolled
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced results from an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting, reporting Phase 1 findings from the two-part IMproveMF study. The safety results from the dose escalation Part 1 suggest the tolerability of RYTELO (imetelstat), a first-in-class telomerase inhibitor, in combination with ruxolitinib as frontline therapy in patients with intermediate-1 (INT-1), intermediate-2 (INT-2) or high-risk (HR) myelofibrosis (MF). Based on the dose escalation findings in Part 1, imetelstat 9.4 mg/kg dosed every four weeks with ruxolitinib was the selected dose for the dose expansion Part 2 of the study, which is currently enrolling patients.